Anupam Rama
Stock Analyst at JP Morgan
(3.50)
# 930
Out of 4,981 analysts
271
Total ratings
44.75%
Success rate
6.24%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Anupam Rama
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IDYA IDEAYA Biosciences | Maintains: Overweight | $72 → $74 | $24.93 | +196.83% | 10 | Sep 3, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Overweight | $55 → $70 | $52.60 | +33.08% | 10 | Sep 3, 2025 | |
| SLDB Solid Biosciences | Maintains: Overweight | $15 → $13 | $5.31 | +144.82% | 8 | Aug 14, 2025 | |
| ORIC ORIC Pharmaceuticals | Maintains: Overweight | $20 → $17 | $10.86 | +56.54% | 5 | Aug 14, 2025 | |
| OLMA Olema Pharmaceuticals | Maintains: Overweight | $28 → $29 | $8.00 | +262.50% | 5 | Aug 14, 2025 | |
| KOD Kodiak Sciences | Upgrades: Neutral | $15 | $9.92 | +51.21% | 7 | Aug 14, 2025 | |
| VERA Vera Therapeutics | Maintains: Overweight | $56 → $53 | $24.53 | +116.06% | 10 | Aug 7, 2025 | |
| COGT Cogent Biosciences | Maintains: Overweight | $29 → $30 | $12.81 | +134.19% | 7 | Aug 7, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Overweight | $35 → $37 | $25.40 | +45.67% | 17 | Aug 4, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Neutral | $140 → $145 | $143.60 | +0.97% | 18 | Jul 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $14 | $15.70 | -10.83% | 8 | Jul 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $24 | $17.91 | +34.00% | 17 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $80 | $23.20 | +244.83% | 12 | Jul 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $19 → $9 | $6.01 | +49.75% | 10 | Jul 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $104 → $117 | $31.23 | +274.64% | 3 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $41 | $16.37 | +150.46% | 10 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $44 → $51 | $32.48 | +57.02% | 12 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $34 | $7.38 | +360.70% | 4 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $44 | $25.00 | +76.00% | 4 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $24.80 | +20.97% | 1 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $17 | $8.02 | +111.97% | 13 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $40 | $37.01 | +8.08% | 3 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $125 | $82.20 | +52.07% | 6 | Oct 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $2.98 | - | 1 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.59 | - | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $2.09 | - | 3 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $13 | $2.55 | +409.80% | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $80 → $90 | $6.01 | +1,397.50% | 2 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $250 | $12.22 | +1,945.83% | 7 | Jul 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $6.97 | - | 3 | Mar 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $58 | $53.32 | +8.78% | 1 | Dec 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $7 → $12 | $13.69 | -12.31% | 2 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $29 → $37 | $5.23 | +607.46% | 6 | Oct 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $55 | $59.68 | -7.84% | 3 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $1.61 | +1,639.13% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $54 | $36.50 | +47.95% | 10 | Mar 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $0.77 | +5,713.20% | 1 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $27 | $13.18 | +104.93% | 1 | Oct 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $133 → $137 | $468.58 | -70.76% | 9 | May 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $39 | $8.59 | +354.02% | 1 | Dec 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $29 → $48 | $7.85 | +511.46% | 5 | Jul 12, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $9.74 | - | 2 | May 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $18 | $0.35 | +5,048.74% | 2 | Mar 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $1.47 | +1,940.82% | 1 | Dec 4, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $60.96 | - | 2 | Nov 16, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.24 | - | 2 | Jul 21, 2017 |
IDEAYA Biosciences
Sep 3, 2025
Maintains: Overweight
Price Target: $72 → $74
Current: $24.93
Upside: +196.83%
BridgeBio Pharma
Sep 3, 2025
Maintains: Overweight
Price Target: $55 → $70
Current: $52.60
Upside: +33.08%
Solid Biosciences
Aug 14, 2025
Maintains: Overweight
Price Target: $15 → $13
Current: $5.31
Upside: +144.82%
ORIC Pharmaceuticals
Aug 14, 2025
Maintains: Overweight
Price Target: $20 → $17
Current: $10.86
Upside: +56.54%
Olema Pharmaceuticals
Aug 14, 2025
Maintains: Overweight
Price Target: $28 → $29
Current: $8.00
Upside: +262.50%
Kodiak Sciences
Aug 14, 2025
Upgrades: Neutral
Price Target: $15
Current: $9.92
Upside: +51.21%
Vera Therapeutics
Aug 7, 2025
Maintains: Overweight
Price Target: $56 → $53
Current: $24.53
Upside: +116.06%
Cogent Biosciences
Aug 7, 2025
Maintains: Overweight
Price Target: $29 → $30
Current: $12.81
Upside: +134.19%
Apellis Pharmaceuticals
Aug 4, 2025
Maintains: Overweight
Price Target: $35 → $37
Current: $25.40
Upside: +45.67%
Neurocrine Biosciences
Jul 31, 2025
Maintains: Neutral
Price Target: $140 → $145
Current: $143.60
Upside: +0.97%
Jul 30, 2025
Upgrades: Neutral
Price Target: $14
Current: $15.70
Upside: -10.83%
Jul 29, 2025
Upgrades: Neutral
Price Target: $24
Current: $17.91
Upside: +34.00%
Jul 24, 2025
Maintains: Overweight
Price Target: $42 → $80
Current: $23.20
Upside: +244.83%
Jul 22, 2025
Downgrades: Neutral
Price Target: $19 → $9
Current: $6.01
Upside: +49.75%
Mar 27, 2025
Maintains: Overweight
Price Target: $104 → $117
Current: $31.23
Upside: +274.64%
Mar 20, 2025
Maintains: Overweight
Price Target: $39 → $41
Current: $16.37
Upside: +150.46%
Mar 13, 2025
Maintains: Overweight
Price Target: $44 → $51
Current: $32.48
Upside: +57.02%
Mar 5, 2025
Maintains: Overweight
Price Target: $39 → $34
Current: $7.38
Upside: +360.70%
Feb 26, 2025
Maintains: Overweight
Price Target: $42 → $44
Current: $25.00
Upside: +76.00%
Feb 25, 2025
Initiates: Overweight
Price Target: $30
Current: $24.80
Upside: +20.97%
Nov 12, 2024
Maintains: Overweight
Price Target: $16 → $17
Current: $8.02
Upside: +111.97%
Nov 5, 2024
Maintains: Overweight
Price Target: $39 → $40
Current: $37.01
Upside: +8.08%
Oct 4, 2024
Maintains: Overweight
Price Target: $100 → $125
Current: $82.20
Upside: +52.07%
Sep 30, 2024
Initiates: Neutral
Price Target: n/a
Current: $2.98
Upside: -
May 15, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.59
Upside: -
Apr 22, 2024
Upgrades: Neutral
Price Target: n/a
Current: $2.09
Upside: -
Apr 1, 2024
Maintains: Overweight
Price Target: $11 → $13
Current: $2.55
Upside: +409.80%
Aug 16, 2023
Maintains: Neutral
Price Target: $80 → $90
Current: $6.01
Upside: +1,397.50%
Jul 13, 2022
Downgrades: Neutral
Price Target: $250
Current: $12.22
Upside: +1,945.83%
Mar 8, 2022
Downgrades: Neutral
Price Target: n/a
Current: $6.97
Upside: -
Dec 10, 2021
Initiates: Overweight
Price Target: $58
Current: $53.32
Upside: +8.78%
Nov 5, 2021
Upgrades: Neutral
Price Target: $7 → $12
Current: $13.69
Upside: -12.31%
Oct 25, 2021
Upgrades: Neutral
Price Target: $29 → $37
Current: $5.23
Upside: +607.46%
Oct 12, 2021
Upgrades: Overweight
Price Target: $55
Current: $59.68
Upside: -7.84%
Aug 10, 2021
Initiates: Overweight
Price Target: $28
Current: $1.61
Upside: +1,639.13%
Mar 1, 2021
Downgrades: Neutral
Price Target: $54
Current: $36.50
Upside: +47.95%
Jan 11, 2021
Initiates: Overweight
Price Target: $45
Current: $0.77
Upside: +5,713.20%
Oct 12, 2020
Initiates: Overweight
Price Target: $27
Current: $13.18
Upside: +104.93%
May 7, 2020
Downgrades: Neutral
Price Target: $133 → $137
Current: $468.58
Upside: -70.76%
Dec 24, 2019
Initiates: Overweight
Price Target: $39
Current: $8.59
Upside: +354.02%
Jul 12, 2019
Downgrades: Neutral
Price Target: $29 → $48
Current: $7.85
Upside: +511.46%
May 10, 2018
Upgrades: Overweight
Price Target: n/a
Current: $9.74
Upside: -
Mar 6, 2018
Maintains: Overweight
Price Target: $15 → $18
Current: $0.35
Upside: +5,048.74%
Dec 4, 2017
Initiates: Overweight
Price Target: $30
Current: $1.47
Upside: +1,940.82%
Nov 16, 2017
Upgrades: Neutral
Price Target: n/a
Current: $60.96
Upside: -
Jul 21, 2017
Downgrades: Neutral
Price Target: n/a
Current: $1.24
Upside: -